Secukinumab-induced paradoxical pustular psoriasis

Clin Exp Dermatol. 2019 Jan;44(1):72-73. doi: 10.1111/ced.13731. Epub 2018 Aug 20.

Authors

S Dogra¹, A Bishnoi¹, T Narang¹, S Handa¹

Affiliation

¹ Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research (PGIMER), Sector 12, Chandigarh, 160012, India.

PMID: 30129214
DOI: 10.1111/ced.13731

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal, Humanized
Dermatologic Agents / therapeutic use
Humans
Infliximab / therapeutic use
Injections, Subcutaneous
Interleukin-17 / antagonists & inhibitors
Male
Psoriasis / chemically induced*
Psoriasis / drug therapy
Skin Diseases, Vesiculobullous / chemically induced
Young Adult

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Dermatologic Agents
Interleukin-17
Infliximab
secukinumab